oasis-4 semaglutide Novo Nordisk's Wegovy® pill (oral 25 mg, once daily) has just been approved by the US FDA as the first oral GLP‑1 receptor agonist for long‑term weight management and CV risk Novo Nordisk's Wegovy® pill OASIS
Description
Bupropion can cause side effects like dry mouth, insomnia, and headaches
Ross Agner and Mikkel Agersnap for their review and input to the manuscript, and Lisa Langley (AXON Communications) for medical writing and editorial assistance
Ironically, Bri and I weigh exactly the same when we started
Who can take GLP-1 for weight loss
But whats the science behind these medications
"Retatrutide FDA Approval Timeline & Status 2025-2027." November 2025.
